Bradshaw feted for 20 years with Gilbane Building Co.
Jack Bradshaw was honored recently for his 20 years of service at Gilbane Building Company. In his time with Gilbane, Bradshaw has supervised the completion of more than $2 billion in public sector projects, including the Integrated Sciences Building at UMass Amherst, Salem High School, Malden High School, Boston D.N.D. Schools, Brookline High School, Worcester Trial Court, Plymouth Trial Court, Logan Modernization Infrastructure, the MassMutual Center, Worcester Convention Center and Worcester Psychiatric Hospital.
Bradshaw has been the recipient of four of the company’s Thomas & William Project Achievement Awards for outstanding leadership, commitment to quality, safety, client focus and satisfaction. Before coming to Gilbane, Bradshaw served as director of the Newburyport Redevelopment Authority and was involved in the resurrection of the city in the 1970s. He is a graduate of the Harvard University Kennedy School of Government and has attended St. Bonaventure University.
Resolute Financial named fastest grower
Resolute Financial was ranked as the 25th fastest growing independent financial advisory firm in the U.S. by Financial Advisor magazine. Resolute has made the magazine’s list in the competitive category of Growth of Assets Manage for three years in a row.
The nationwide survey is a ranking of independent registered investment advisory firms based on assets being managed during the past year. To be eligible, firms had to be registered as an independent advisor and offer financial planning and investment services, primarily to individuals and families.
Resolute Financial is a fee-only financial planning and investment advisory firm, with offices in Newburyport, Chelmsford and Wakefield. Newburyport residents Tom Dwyer and Chuck Johnson are managing partners in the firm. For more, Chuck Johnson at 978-463-8771 or www.ResoluteFinancial.com.
BioMolecular Products, Inc. announces patent
BioMolecular Products, Inc. announced the issuance of a patent covering certain molecular structures of its Lym-X-Sorb technology. The patent, U.S. number 8,222,233, covers claims relating to drug-delivery technology and for nutritional supplementation using Lym-X-Sorb’s lipid matrix with specified molecular ratios. This brings to nine the number of active U.S. patents surrounding LXS technology held by BMP.